Peer-reviewedCC BYJournal of clinical medicine
Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models
- 1Geron Corporation, Foster City, CA 94404, USA; (F.H.); (J.E.)
- 2Janssen Research & Development, LLC, Spring House, PA 19477, USA
Related
- Urinary apoptosis inhibitor of macrophage reflects renal inflammation and tubular damage in ANCA-associated vasculitis
- The Role of Telomerase in Cellular Stress Response—Therapeutic Potential of Telomerase Inhibitors
- Human Telomerase RNA Accumulation in Cajal Bodies Facilitates Telomerase Recruitment to Telomeres and Telomere Elongation
- Low- to high-throughput analysis of telomerase modulators with Telospot
- LKB1 promotes lung adenocarcinoma cell senescence by suppressing the O-GlcNAc glycosylation-mediated activation of telomerase
BibTeX
@article{huang2026combining,
title = {{Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models}},
author = {Fei Huang and Joshua J. Rusbuldt and Leopoldo Luistro and Heidi Colton and Joseph Eid},
journal = {Journal of clinical medicine},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13665851},
note = {CC BY},
}
RIS
TY - JOUR
TI - Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models
AU - Fei Huang
AU - Joshua J. Rusbuldt
AU - Leopoldo Luistro
AU - Heidi Colton
AU - Joseph Eid
PY - 2026
DA - 2026/09/23
JO - Journal of clinical medicine
UR - https://europepmc.org/article/PMC/PMC13665851
SN - 2077-0383
ER -